SCHEMBL1900471

SCHEMBL1900471

CC(=O)NCCCNC(C)=O

nearest known ligand 0.82

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.82
MAPK1 P28482 1/20 0.82
HIF1A Q16665 1/20 0.82
PAOX Q6QHF9 3/20 0.64
ADRA1A P35348 1/20 0.61
TSHR P16473 1/20 0.57
ALDH1A1 P00352 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GLA P06280 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
F13A1 P00488 1/20 0.43
EPHX1 P07099 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860791 0.93 KDM4E (0.94) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21306389 0.91 PAOX (0.74) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL14739632 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL10937726 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
Hexamethylenebisacetamide SCHEMBL61980 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL14740132 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL1847535 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL14739904 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL6516953 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL1900654 0.90 KDM4E (1.00) KDM4EMAPK1HIF1APAOXADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0192299-B1 PROCESS FOR THE PREPARATION OF PYRIMIDINE AND 2-ALKYLPYRIMIDINE STAMICARBON B.V. (NL) 1990-08-29 EP claimed
EP-0131374-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PENEM DERIVATIVES PFIZER INC. (US) 1988-11-23 EP claimed
US-4775755-A DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE STAMICARBON B. V. (NL) 1988-10-04 US claimed
US-4619783-A BACTERICIDES PFIZER INC. (US) 1986-10-28 US claimed
EP-0192299-A1 Process for the preparation of pyrimidine and 2-alkylpyrimidine STAMICARBON B.V. (NL) 1986-08-27 EP claimed
US-20240239934-A1 FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE TOSOH CORPORATION (JP) 2024-07-18 US disclosed
EP-3157978-B1 STRICTLY SEGMENTED THERMOPLASTIC ELASTOMERS AS BIODEGRADABLE BIOMATERIALS SYMO CHEM B V (NL) 2021-08-11 EP disclosed
EP-3778573-A1 COMPOUND WITH ANTICANCER ACTIVITY Kyowa Kirin Co., Ltd. (JP) 2021-02-17 EP disclosed
US-10562767-B2 Liquid-organic hydrogen carrier systems based on catalytic peptide formation and hydrogenation YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2020-02-18 US disclosed
WO-2019189778-A1 COMPOUND WITH ANTICANCER ACTIVITY 協和発酵キリン株式会社 2019-10-03 WO disclosed
US-20170283257-A1 LIQUID-ORGANIC HYDROGEN CARRIER SYSTEMS BASED ON CATALYTIC PEPTIDE FORMATION AND HYDROGENATION YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2017-10-05 US disclosed
EP-3189006-A1 LIQUID-ORGANIC HYDROGEN CARRIER SYSTEMS BASED ON CATALYTIC PEPTIDE FORMATION AND HYDROGENATION Yeda Research and Development Co., Ltd. (IL) 2017-07-12 EP disclosed
US-6583164-B1 Lyophilized imidazole-1-yl or 1,2,4-triazole-1-yl quaternized with a alklycarbonyloxy alkyl group eliminated in vivo; a saccharide; 4-acetoxymethyl-1-(3-(2-oxo-3-(4-(1H-tetrazol-yl) phenyl)-1-imidazolydinyl)butyl)-1H-1,2,4-triazolium chloride TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-24 US disclosed
US-5421868-A Ink composition INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1995-06-06 US disclosed
US-5173112-A Nonplugging, improved storage stability E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-12-22 US disclosed
EP-0192299-B1 PROCESS FOR THE PREPARATION OF PYRIMIDINE AND 2-ALKYLPYRIMIDINE STAMICARBON B.V. (NL) 1990-08-29 EP disclosed
US-4775755-A DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE STAMICARBON B. V. (NL) 1988-10-04 US disclosed
US-4775755-A DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE STAMICARBON B. V. (NL) 1988-10-04 US disclosed
EP-0192299-A1 Process for the preparation of pyrimidine and 2-alkylpyrimidine STAMICARBON B.V. (NL) 1986-08-27 EP disclosed
EP-0192299-A1 Process for the preparation of pyrimidine and 2-alkylpyrimidine STAMICARBON B.V. (NL) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562767-B2 Liquid-organic hydrogen carrier systems based on catalytic peptide formation and hydrogenation DDC, ADH1C, MLEC KDM4E 2373/4885MAPK1 3077/4885HIF1A 2893/4885
US-20170283257-A1 LIQUID-ORGANIC HYDROGEN CARRIER SYSTEMS BASED ON CATALYTIC PEPTIDE FORMATION AND HYDROGENATION DDC, ADH1C, MLEC KDM4E 2373/4885MAPK1 3077/4885HIF1A 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.